financetom
Business
financetom
/
Business
/
Canfor Pulp Q3 sales miss expectations amid weak demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Canfor Pulp Q3 sales miss expectations amid weak demand
Nov 5, 2025 3:33 PM

Overview

* Canfor Pulp Q3 sales miss analyst expectations amid global pulp market weakness

* Company reports Q3 operating loss of C$16 mln, net loss of C$12 mln

* Pulp production up 5% qtr/qtr, but demand remains weak

Outlook

* Company expects weak pulp market conditions to persist in Q4 2025

* Maintenance outage to reduce Q4 2025 pulp production by 10,000 tonnes

* Management working to mitigate risk of financial covenant non-compliance

Result Drivers

* GLOBAL PULP MARKET WEAKNESS - Co cites depressed global pulp market fundamentals and weak demand in China and North America as key factors for Q3 results

* INVENTORY LEVELS - Elevated pulp producer inventories contributed to ongoing pricing declines, impacting Q3 results

* PRODUCTION IMPROVEMENT - Pulp production increased by 5% qtr/qtr, partially offsetting negative market impacts

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Sales Miss C$164.60 C$167.80

mln mln (2

Analysts

)

Q3 Net -C$12.40

Loss mln

Q3 -C$7.20

Adjusted mln

Operatin

g Loss

Q3 Basic -C$0.19

Loss per

Share

Q3 -C$16

Operatin mln

g Loss

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the paper products peer group is "buy."

* Wall Street's median 12-month price target for Canfor Pulp Products Inc ( CFPUF ) is C$0.73, about 46.2% above its November 5 closing price of C$0.39

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved